In a nutshell This phase 1/2 trial aims to test the safety and effectiveness of a combined treatment with the new vaccine LPV7 and TLR agonists in advanced melanoma patients after surgery. The main outcome to be measured will be the treatment toxicity and response of the tumors to the treatment. This trial is recruiting in Houston, Texas and...
Read MoreIn a nutshell This study investigated the effectiveness of ipilimumab (Yervoy) in patients with stage 3 melanoma with high risk of recurrence (when cancer comes back). Researchers suggested that ipilimumab (at a dose of 10mg/kg) significantly increased survival of these patients. Some background Ipilimumab is an antibody that helps the...
Read More
In a nutshell This review summarized evidence on emerging immunotherapies for prostate cancer. Authors concluded that immunotherapeutic agents show promising early results in patients with advanced prostate cancer and few symptoms. Some background Immunotherapies are currently under investigation as possible cancer treatments. Immunotherapies...
Read More
In a nutshell This review examined the safety and effectiveness of dabrafenib (Tafinlar) and trametinib (Mekinist) for inoperable metastatic melanoma. Researchers concluded that this combined treatment is an important therapy option for patients with metastatic melanoma. Some background Some melanoma patients have a mutation...
Read MoreIn a nutshell The authors investigated the correlation between the level of PD-1, an important protein in immune system, and clinical response of melanoma patients treated with anti-PD1 therapy. The authors concluded that the level of PD-1 was significantly associated with clinical response in metastatic melanoma patients receiving anti-PD1...
Read More
In a nutshell The authors analyzed the effectiveness of ipilimumab (Yervoy) combined with fotemustine (Muphoran) in advanced melanoma patients. Some background In advanced melanoma (stage III/IV), cancer spreads rapidly from the skin to other parts of the body. This is known as...
Read More
In a nutshell The authors determined the benefit of docetaxel (Taxotere), bevacizumab (Avastin) and hormone therapy in treating prostate cancer patients with biochemical recurrence. Some background Biochemical recurrence can occur in prostate cancer patients after primary treatment. This means there is an increase in PSA. PSA...
Read MoreIn a nutshell The authors reviewed different immunotherapies for advanced melanoma. Some background In advanced melanoma (stage III/IV), cancer spreads from the skin to other parts of the body. Immunotherapy is a common treatment used in advanced melanoma. It uses the body’s own immune system to fight cancer. This...
Read More
In a nutshell The authors compared nivolumab (Opdivo) in combination with ipilimumab (Yervoy) to ipilimumab alone in the treatment of advanced melanoma. Some background In the advanced stages of melanoma (stage III/IV), cancer spreads from the skin to other parts of the body. In many melanoma...
Read More
In a nutshell The authors determined the benefit of measuring tumor cells in the blood for the treatment of advanced melanoma. Some background Treatment options for advanced melanoma include targeted therapy (targeting specific genes or proteins) and immunotherapy (using the body’s own immune system to fight cancer)....
Read MoreIn a nutshell This study analyzed whether the drug bevacizumab is linked with increased rates of surgical complications. Some background In locally advanced rectal cancer the cancer has spread beyond the lining of the rectum or has spread to the nearby lymph nodes. The standard treatment for patients with locally advanced rectal cancer is...
Read More
In a nutshell The authors aimed to evaluate the use of Gleason scores in predicting the outlook of metastatic prostate cancer. Some background The Gleason grading system is from 2-10. It describes how different the cancer cells look from normal cells and predicts the likelihood of the tumor spreading. The lower the score, the less likely it...
Read More
